SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.

TSXV:SQD.H - Post by User

SQI Diagnostics Inc > Azova Marketing launch...?

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Apr 04, 2022 11:59am

130 Views

Post# 34573313

RE:Azova Marketing launch...?

I wonder if the Company/Shares will be marketed to the investment community before....

the major expected jump in revenues to $ 5-$6M for Q2 (3 mo ended March 31) - likely due for release next month

Azova starts to open the flood-gates on it's own campaign to induce sales of Exact Antibody tests throughout the US

Corrections made to previous post

mercedesman wrote: ...targeted for mid - April (per AGM presentation).

Roughly about two weeks from now !

Thus should begin the second major revenue stream. In total there should be 4 streams...none of which have been revealed to the market, in any meaningful way ... just yet.

1. Mobile PCR testing (largely via the PBI acquisition with captive Corporate Clients nurtured by PBI)...possibly fueled by the next Covid wave as well (that is startiing now in NA). Fiscal Q2 should be very interesting...especially as PCR testing starts to ramp up again

2. Exact Antibody test (now approved by NY for sales accross the US, as long as results are collected & analyzed in NY labs) Initially the bulk of the Sales will happen via the Azova marketing machine. Then likely by other means (other DTC providers, corporate clients, etc.) Fiscal Q3 and Q4 should be very interesting.

3. Time to start monetizing transplant Diagnostics. Starting with lungs and UHN, but it sounds like there are major plans to have centers all acrross the US that will use SQI technology to assess, and repair lungs...as well as, eventually, other organs. Goals are: to clean up the donated organs, increase the number of matches, and reduce rate of ultimate organ rejection. Long Covid and recovered hospitalized Covid patients (and it's inhereant underlying damage to organs) may cause this industry to explode. 2022 & 2023? Coronavirus: Kidney Damage Caused by COVID-19 | Johns Hopkins Medicine

4. Rali-DX as a critical diagnostic test to determine the severity of infections (not just Covid) Starts with a Health Canada Approval (any time?). Reading between the lines, I think that this could be sold as a follow-up test for anyone that tests positive for Covid or Pneumonia, and who wants more information (i.e how worried they should be - and whether or not they shoould take additional or immediate steps (e.g admission to hospital, antiviral pills, etc.). It sounds like legacy equipment/machines can be used to process such tests quickly and accurately. Q4 and Q1 and 2023?

Investors might be (make that most likely will be) surprised by the rapid growth in revenues - almost out of no where, and almost over-night !

That and a serious marketing/media launch, should provide the rocket fuel for many Qtrs to come.

MM